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Introduction:	Persons	with	haemophilia	A	(PwHA)	with	inhibitors	to	factor	VIII	often	
experience	decreased	health‐related	outcomes.	In	HAVEN	1	(NCT02622321),	there	
was	a	statistically	significant	reduction	in	bleeding	with	emicizumab	prophylaxis	ver‐
sus	no	prophylaxis.
Aim:	Describe	health‐related	outcomes	in	PwHA	with	inhibitors	in	HAVEN	1.
Methods:	 PwHA	with	 inhibitors	 aged	 ≥12	years	 previously	 on	 episodic	 bypassing	
agents	 (BPAs)	were	 randomized	 to	 emicizumab	 prophylaxis	 (Arm	A;	 n	=	35)	 or	 no	
prophylaxis	 (Arm	 B;	 n	=	18);	 participants	 previously	 on	 BPA	 prophylaxis	 received	
emicizumab	prophylaxis	(Arm	C;	n	=	49).	Health‐related	outcomes	assessed	at	base‐
line	and	monthly	 thereafter:	Haemophilia	Quality	of	Life	Questionnaire	 for	Adults	
(Haem‐A‐QoL),	 Haemophilia‐specific	 Quality	 of	 Life	 Questionnaire	 for	 Children	
Short	Form	(Haemo‐QoL	SF),	EuroQol	5‐Dimensions	5‐Levels	(EQ‐5D‐5L)	index	util‐
ity	score	(IUS)	and	visual	analogue	scale	(EQ‐VAS)	and	work/school	days.	Days	hospi‐
talized	also	recorded.
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1  | INTRODUC TION
Despite	advances	in	the	treatment	of	haemophilia	A	in	the	past	de‐
cades,1	 current	 standard	 approaches	 continue	 to	 require	 frequent	
and	time‐consuming	intravenous	infusions	of	factor	VIII	(FVIII)	con‐
centrates.1‐3	Up	to	20%	of	persons	with	haemophilia	A	(PwHA)	de‐
velop	alloantibodies	(inhibitors)	to	FVIII	treatments,	typically	within	
the	first	10‐15	days	of	 treatment.4,5	 Inhibitors	are	classified	as	 low	
titre	 (<5	 Bethesda	 units	 [BU]/mL)	 or	 high	 titre	 (>5	BU/mL	 at	 least	
once)	based	on	the	highest	documented	 inhibitor	 level	and	the	oc‐
currence	of	an	anamnestic	response	after	re‐exposure	to	factor	con‐
centrate.6	 Among	 PwHA	with	 inhibitors,	 therapeutic	 options	 have	
been	more	limited,	particularly	burdensome	and	suboptimally	effec‐
tive.7‐12	Current	guidelines	recommend	immune	tolerance	induction	
(ITI)	to	eliminate	high‐titre	inhibitors	as	first‐line	treatment	in	these	
individuals,	 which	 can	 enable	 effective	 replacement	 therapy	 and	
make	prophylaxis	feasible	in	order	to	prevent	or	lessen	the	negative	
impact	of	persistent	inhibitors	on	patients’	morbidity	and	quality	of	
life.13‐18	However,	ITI	is	associated	with	high	costs,	involves	frequent,	
prolonged	 infusions	 and	 is	 not	 always	 effective.19,20	 Bleeding	 in	
PwHA	with	inhibitors	requires	bypassing	agents	(BPAs;	ie,	activated	
prothrombin	complex	concentrates,	recombinant	factor	VIIa).12
Until	recently,	the	only	prophylaxis	regimens	for	PwHA	with	in‐
hibitors	with	acceptable	outcomes	required	intravenous	infusions	of	
BPAs	every	other	day,	with	dosing	regimens	varying	from	three	times	
a	week	to	daily	in	clinical	practice.10‐12,21	Despite	BPA	prophylaxis,	
PwHA	with	 inhibitors	 have	 significant	 breakthrough	 bleeding,10,12 
and	 often	 experience	 poor	 health‐related	 quality	 of	 life	 (HRQoL),	
increased	health	care	costs,	joint	pain	and	other	orthopaedic	issues,	
and	missed	days	of	work	and	school	due	to	bleeding.22‐26
Emicizumab	 (HEMLIBRA®;	 F.	 Hoffmann‐La	 Roche,	 Basel,	
Switzerland)	 was	 developed	 to	 address	 the	 unmet	 needs	 of	
PwHA	with	 inhibitors	 for	 effective,	 less	 burdensome	 prophylaxis.	
Emicizumab	 is	 a	 humanized	 bispecific	 antibody	 that	 bridges	 acti‐
vated	factor	IX	and	factor	X,	restoring	the	function	of	missing	acti‐
vated	FVIII	and	haemostasis	even	in	the	presence	of	FVIII	inhibitors.	
High	 subcutaneous	 bioavailability27	 and	 a	 4‐	 to	 5‐week	 half‐life28 
allow	emicizumab	to	be	administered	subcutaneously	once	weekly.29 
Emicizumab	has	been	approved	in	several	countries	for	prophylaxis	
to	 prevent	 or	 reduce	 bleeding	 frequency	 in	 adult	 and	 paediatric	
PwHA	with	FVIII	inhibitors.
In	the	HAVEN	1	Phase	3	clinical	study	of	PwHA	with	inhibitors	
(NCT02622321),	emicizumab	prophylaxis	was	associated	with	 sta‐
tistically	significant	and	clinically	meaningful	reductions	in	bleeding	
versus	 no	 prophylaxis.	 Annualized	 bleeding	 rate	 (95%	 confidence	
interval	 [CI])	 for	 treated	bleeds	was	2.9	 (1.7,	5.0)	with	emicizumab	
prophylaxis	and	23.3	(12.3,	43.9)	with	no	prophylaxis	(episodic	BPAs	
only);	representing	an	87%	difference	in	favour	of	emicizumab	pro‐
phylaxis	(risk	ratio:	0.13;	P < 0.001).29	Zero‐treated	bleeding	events	
were	 experienced	 by	 63%	 on	 emicizumab	 prophylaxis	 and	 6%	 on	
no	prophylaxis.	In	an	intra‐individual	comparison	among	those	pre‐
viously	 using	BPA	prophylaxis	 in	 a	 prospective	 non‐interventional	
study	 (NIS;	 NCT02476942),	 emicizumab	 prophylaxis	 resulted	 in	 a	
79%	decrease	in	bleeding	rates	(P	<	0.001).29
The	purpose	of	 the	present	 paper	 is	 to	 provide	 a	 detailed	 de‐
scription	of	HRQoL	and	health	status	outcomes	in	PwHA	with	inhib‐
itors	in	HAVEN	1.
2  | MATERIAL S AND METHODS
HAVEN	1	was	a	multicentre,	open‐label,	 randomized,	Phase	3	trial	
conducted	 in	 43	 centres	 in	 14	 countries	worldwide.	 The	 protocol	
was	approved	by	the	institutional	review	board	at	each	centre	and	
adhered	to	Good	Clinical	Practice	guidelines.	The	protocol	 for	 the	
HAVEN	1	clinical	trial	has	been	described	previously29	and	is	sum‐
marized	briefly	here	and	in	Figure	1.
PwHA	(any	severity)	with	inhibitors	aged	≥12	years	were	enrolled	if	
they	had	a	history	of	high‐titre	FVIII	inhibitors	(≥5	BU/mL),	had	received	
BPAs	to	treat	or	control	bleeding	for	≥24	weeks	before	study	entry	and,	
in	the	previous	24	weeks,	had	≥6	bleeds	while	on	episodic	BPAs	or	≥2	
bleeds	while	on	prophylactic	BPAs.
Results:	At	week	25,	differences	(ANCOVA)	in	adjusted	mean	scores	(95%	confidence	
interval)	 favoured	Arm	A	versus	B	 for	Haem‐A‐QoL	“Total”	 score	 (14.0	 [5.6,	22.5];	
P	=	0.002)	 and	 “Physical	Health”	 (21.6	 [7.9,	 35.2];	P	=	0.003);	 EQ‐VAS	 (−9.7	 [−17.6,	
−1.82];	P	=	0.017);	and	IUS	(−0.16	[−0.25,	−0.07];	P	=	0.001);	mean	scores	are	compa‐
rable	in	Arms	A	and	C.	Throughout	the	study,	a	greater	proportion	of	participants	on	
emicizumab	 prophylaxis	 than	 no	 prophylaxis	 exceeded	 questionnaire‐specific	 re‐
sponder	thresholds.	Mean	proportion	of	missed	work	days	and	number	of	days	hos‐
pitalized	were	lower	with	emicizumab	prophylaxis	than	no	prophylaxis.
Conclusions:	In	PwHA	with	inhibitors,	emicizumab	prophylaxis	was	associated	with	
substantial	and	meaningful	improvements	in	health‐related	outcomes.
K E Y W O R D S
emicizumab,	factor	VIII	inhibitors,	haemophilia	A,	health‐related	quality	of	life,	prophylaxis
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Participants	 on	 episodic	 BPA	 treatment	 before	 study	 entry	
were	 randomized	 2:1	 to	 receive	 subcutaneous	 emicizumab	 pro‐
phylaxis	(Arm	A)	or	no	prophylaxis	(Arm	B;	only	episodic	BPAs	al‐
lowed).	Participants	previously	on	prophylactic	BPAs	all	received	
emicizumab	prophylaxis	(Arm	C).	Participants	who	had	previously	
participated	 in	 the	NIS,	but	were	unable	to	enrol	 into	Arms	A,	B	
or	 C	 before	 enrolment	 closed,	 received	 emicizumab	 prophylaxis	
in	Arm	D	(Figure	1).	The	results	for	Arm	D	are	not	included	in	the	
present	report	because	there	were	too	few	participants	(n	=	7)	for	
a	meaningful	analysis	of	their	outcomes.
Emicizumab	prophylaxis	was	administered	at	3.0	mg/kg	weekly	
for	4	weeks	followed	by	1.5	mg/kg	weekly.
2.1 | Outcome measures
2.1.1 | Quality of life
Haemophilia Quality of Life Questionnaire for Adults 
(Haem‐A‐QoL)
The	Haem‐A‐QoL	 is	 a	 validated,	 haemophilia‐specific	 instrument	 for	
evaluating	HRQoL	in	PwHA	aged	≥18	years.30‐32	This	46‐item	measure	
consists	of	10	domains	(“Physical	Health,”	“Feelings,”	“View	of	Yourself,”	
“Sports	 &	 Leisure,”	 “Work	 &	 School,”	 “Dealing	 with	 Haemophilia,”	
“Treatment,”	 “Future,”	 “Family	 Planning”	 and	 “Partnerships	 &	
Sexuality”),	each	scored	separately	and	combined	 to	create	a	 “Total”	
score.	Response	options	range	from	“Never”	(1)	to	“All	of	the	time”	(5)	on	
a	5‐point	Likert	scale,	with	an	additional	“Not	applicable”	option	avail‐
able	for	“Sports	&	Leisure,”	“Family	Planning”	and	“Work	&	School.”	In	
order	to	score	all	responses	in	the	same	direction,	some	items	of	the	do‐
mains	“View	of	Yourself,”	“Sports	&	Leisure,”	“Work	&	School,”	“Dealing	
with	Haemophilia,”	“Treatment”	and	“Future”	were	reverse‐scored.
Haemophilia‐specific Quality of Life assessment for children 
and adolescents Short Form (Haemo‐QoL SF)
The	Haemo‐QoL	SF	is	a	validated,	haemophilia‐specific	instrument	
for	evaluating	HRQoL	 in	PwHA	 in	 two	age	groups	 (I:	4‐7	years;	 II:	
8‐17	years).33	 The	 35‐item	measure	 for	 age	 group	 II	 is	 composed	
of	 nine	 domains	 (“Physical	 Health,”	 “Feelings,”	 “View	 of	 Yourself,”	
“Family,”	 “Friends,”	 “Other	 People,”	 “Sports	 &	 School,”	 “Dealing	
with	 Haemophilia”	 and	 “Treatment”),	 each	 scored	 separately	 and	
combined	to	create	a	“Total”	score.	Response	options	ranged	from	
“Never”	(1)	to	“Always”	(5)	on	a	5‐point	Likert	scale.	Some	items	of	
the	 domains	 “View	 of	 Yourself”,	 “Friends,”	 “Sports	 &	 School”	 and	
“Dealing	with	Haemophilia”	were	reverse‐scored	as	above.
For	 both	 Haem‐A‐QoL	 and	 Haemo‐QoL	 SF	 scales,	 participants	
were	asked	to	consider	their	experience	in	the	previous	4	weeks	when	
responding.	On	both	scales,	all	domain	scores	were	transformed	to	a	
0‐100	scale	with	higher	scores	indicating	greater	impairment.
2.1.2 | Health status
Health	 status	was	 assessed	using	 the	European	Quality	 of	 Life	5‐
Dimensions	5‐levels	 (EQ‐5D‐5L)	questionnaire	and	visual	analogue	
scale	(EQ‐VAS).34,35	The	five	dimensions	of	the	EQ‐5D‐5L	assess	mo‐
bility,	self‐care,	usual	activities,	pain/discomfort	and	anxiety/depres‐
sion;	 each	with	 five	 levels	 of	 severity	 ranging	 from	 “no	problems”	
to	“extreme	problems”.35,36	The	five	dimensions	were	combined	into	
an	index	utility	score	(IUS)	using	the	UK	crosswalk	value	set;	scores	
range	 from	−0.594	 (extreme	problems	 on	 all	 dimensions)	 to	 1	 (no	
problems	 on	 all	 dimensions).37	 On	 the	 EQ‐VAS,	 participants	 indi‐
cated	 their	health	 status	on	a	 thermometer	 ranging	 from	0	 (worst	
imaginable)	 to	100	 (best	 imaginable).	 For	both	EQ‐5D‐5L	 and	EQ‐
VAS,	participants	were	asked	to	report	the	severity	experienced	on	
the	day	the	questionnaire	was	completed.
2.1.3 | Work and school absences
Every	 4	weeks,	 participants	were	 asked	 to	 report	 how	many	 days	
of	work	or	school	they	missed	during	the	previous	4	weeks	due	to	
haemophilia	A,	and	how	many	days	they	should	have	been	at	work	
or	school.
2.1.4 | Hospitalizations
Hospitalizations	were	recorded	in	the	serious	adverse	events	page	
of	the	electronic	case	report	forms	(eCRFs)	by	investigators.
F I G U R E  1  HAVEN	1	Study	design.	
BPA,	bypassing	agent;	PwHA,	persons	
with	haemophilia	A;	R,	randomization.	
aNon‐interventional	study	(NCT02476942)	
collected	real‐world	data	on	bleed	rates	
and	standard‐of‐care	treatments	in	PwHA	
with	inhibitors;	participants	subsequently	
had	the	option	to	enrol	into	HAVEN	1.	
bParticipants	unable	to	enrol	into	Arms	A,	
B	or	C	before	they	closed	to	enrolment	
were	enrolled	in	Arm	D	for	compassionate	
reasons
R
2:1
PwHA with inhibitors on
episodic/prophylactic treatment
with BPAs (from non-
interventional study)b 
(n = 7)   
Emicizumab
Primary analysis:
      ≥24 wk follow-up in Arms A and B
Prior episodic treatment
(n = 53) 
Prior prophylactic treatment
(n = 49) 
No prophylaxis (n = 18)
Emicizumab (n = 35)
Emicizumab
Emicizumab (n = 49) Emicizumab
Arm A
Emicizumab
Arm B (control arm) 
Arm C
Arm D
PwHA with inhibitors aged ≥12 y
on treatment with BPAsa (N = 109)
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2.2 | Data collection and analysis
All	 outcomes,	 except	 for	 hospitalizations,	 were	 recorded	 by	 par‐
ticipants	 using	 an	 electronic,	 handheld	 device	 provided	 during	
the	week	 1	 visit	 and	 before	 administration	 of	 study	medication.	
Participants	were	asked	to	record	all	HRQoL	and	health	status	out‐
comes	every	4	weeks.	In	addition	to	scheduled	assessments,	they	
were	 asked	 to	 complete	 the	 EQ‐5D‐5L	 on	 any	 day	 during	which	
bleeding	occurred.
Demographic	data,	medical	history	and	hospitalizations	were	
collected	 from	 participants’	medical	 records	 on	 an	 eCRF	 by	 cli‐
nicians.	Analysis	of	covariance	(model	 included	treatment	group,	
baseline	 score	 and	 the	 treatment‐by‐baseline	 interaction	 term	
as	 covariates)	 was	 used	 to	 compare	 the	 adjusted	 mean	 scores	
for	 Haem‐A‐QoL	 “Physical	 Health”	 and	 “Total”	 score	 and	 the	
EQ‐5D‐5L	 IUS	 and	EQ‐VAS	between	Arms	A	 and	B	which	were	
included	 as	 type	 1	 error‐controlled	 secondary	 endpoints.	 The	
analysis	 of	 EQ‐5D‐5L	 IUS	 and	 EQ‐VAS	 when	 a	 bleed	 occurred	
(unscheduled	 assessments)	 as	 compared	 with	 when	 no	 bleed	
occurred	 (monthly	 scheduled	 assessments)	 only	 included	 par‐
ticipants	who	 had	 at	 least	 one	 scheduled	 and	 one	 unscheduled	
assessment.
Cumulative	distribution	function	(CDF)	plots	of	the	change	from	
baseline	to	week	25	in	Haem‐A‐QoL	“Physical	Health”	domain	and	
“Total”	scores	were	calculated	for	Arms	A	and	B.
The	 proportion	 of	 participants	 achieving	 an	 improvement	 at	
week	25	larger	than	a	previously	published	responder	threshold	was	
calculated	for	Haem‐A‐QoL	“Total”	score	(−7),	Haem‐A‐QoL	“Physical	
Health”	score	(−10),	EQ‐5D‐5L	IUS	(+0.07)	and	EQ‐VAS	(+7).38‐41
The	 rate	 of	 participant	 compliance	 with	 the	 completion	 of	
each	 questionnaire	 (Haem‐A‐QoL,	 Haemo‐QoL	 SF	 and	 scheduled	
EQ‐5L‐5D)	at	each	time	point	was	calculated	by	dividing	the	number	
of	questionnaires	by	the	total	number	expected	at	that	time.
All	analyses	were	based	on	the	data	cut‐off	used	for	the	primary	
analysis.29
3  | RESULTS
3.1 | Study population
The	 participant	 population	 for	 the	 HAVEN	 1	 study	 has	 been	 de‐
scribed	 previously29	 and	 is	 summarized	 briefly	 here.	 Participants	
previously	 receiving	episodic	BPAs	were	 randomized	2:1	 to	emici‐
zumab	prophylaxis	(Arm	A,	n	=	35)	or	no	prophylaxis	(Arm	B,	n	=	18;	
episodic	BPAs	only),	 and	49	participants	previously	 receiving	pro‐
phylactic	BPAs	received	emicizumab	prophylaxis	in	Arm	C.	Nearly	all	
participants	had	severe	haemophilia	at	diagnosis,	and	>50%	in	each	
treatment	arm	had	experienced	≥9	bleeding	events	in	the	previous	
24	weeks.	Participants	in	Arm	C	were	younger	and	had	a	higher	rate	
of	previous	ITI	than	those	in	Arms	A	and	B	(Table	1).
TA B L E  1  Participant	demographics	and	baseline	characteristics29
Characteristic
Previously on episodic BPAsa
Previously on 
prophylactic BPAsa
Arm A: Emicizumab 
prophylaxis (n = 35) Arm B: No prophylaxis (n = 18)
Arm C: Emicizumab 
prophylaxis (n = 49)
Median	age,	y	(range) 38.0	(12‐68) 35.5	(13‐65) 17.0	(12‐75)
Age	groups
<18	y,	n	(%) 4	(11.4) 2	(11.1) 26	(53.1)
≥18	y,	n	(%) 31	(88.6) 16	(88.9) 23	(46.9)
Race,	n	(%)
Asian 10	(28.6) 3	(16.7) 8	(1.36)
Black	or	African	American 4	(11.4) 4	(22.2) 3	(6.1)
White 21	(60.0) 10	(55.6) 33	(67.3)
Otherb 0	(0.0) 1	(5.6) 5	(10.2)
Bleeding	events	in	previous	24	wk,	n	(%)
<9 11	(31.4) 5	(27.8) 23	(46.9)
≥9 24	(68.6) 13	(72.2) 26	(53.1)
Severe	haemophilia	at	baseline,	n	(%) 31	(88.6) 18	(100.0) 47	(95.9)
Previously	treated	with	ITI,	n	(%) 14	(40.0) 7	(38.9) 33	(67.3)
Highest	historical	inhibitor	titre	levels,c median 
BU	(range)
288.9	(5‐1570) 706.8	(18‐4500) 815.7	(11‐5000)
BPA,	bypassing	agents,	bypassing	agent;	BU,	Bethesda	units;	ITI,	immune	tolerance	induction.
aIncludes	prothrombin	complex	concentrate,	recombinant	factor	VIIa	and	factor	VIII.	
bIncludes	Native	American,	Alaskan	Native,	Native	Hawaiian,	other	Pacific	Islanders	and	unknown.	
cNo	participants	under	5	BU.	
     |  37OLDENBURG Et aL.
3.1.1 | Compliance
Compliance	 with	 completion	 of	 all	 questionnaires	 across	 all	 time	
points	was	≥90%	for	all	outcome	measures	in	all	treatment	arms.
3.1.2 | Haemophilia‐specific Quality of Life in adults 
(Haem‐A‐QoL)
Baseline	mean	Haem‐A‐QoL	“Total”	and	domain	scores	are	listed	in	
Table	2.
Improvements	 in	 Haem‐A‐QoL	 domain	 and	 total	 scores	 with	
emicizumab	prophylaxis	were	seen	as	early	as	week	5,	maintained	
through	week	25	and	generally	similar	regardless	of	previous	treat‐
ment	 regimen	 (Figure	 2A	 and	 3A).	 Among	 participants	 previously	
treated	with	episodic	BPAs,	the	difference	in	adjusted	mean	scores	
between	the	emicizumab	prophylaxis	group	(Arm	A)	and	the	no	pro‐
phylaxis	group	(Arm	B)	at	week	25	was	statistically	significant	in	fa‐
vour	of	emicizumab	for	both	“Total”	(Δ	=	14.01;	95%	CI:	5.56,	22.45;	
P	=	0.0019)	and	“Physical	Health”	domain	(Δ	=	21.55;	95%	CI:	7.89,	
35.22; P	=	0.0029)	scores.
Throughout	 the	 study,	 a	 greater	 proportion	 of	 participants	 in	
the	emicizumab	prophylaxis	groups	(Arms	A	and	C)	than	the	no	pro‐
phylaxis	group	(Arm	B)	achieved	an	improvement	from	baseline	ex‐
ceeding	responder	thresholds38	for	“Total”	(−7	points)	and	“Physical	
Health”	 domain	 (−10	points)	 scores	 (Figure	 S1A,B).	 In	 the	 cumula‐
tive	distribution	plots	of	change	from	baseline	to	week	25	for	both	
the	“Total”	and	“Physical	Health”	domain	scores,	 there	was	a	clear	
separation	between	Arms	A	and	B	throughout	all	potential	levels	of	
change	(Figure	2B	and	3B).
Emicizumab	 prophylaxis	 also	 produced	 notable	 improvements	
from	baseline	in	other	domains	of	the	Haem‐A‐QoL	(Table	3),	and	im‐
provements	were	qualitatively	similar	 regardless	of	previous	treat‐
ment	regimen.	There	was	no	notable	change	in	the	no	prophylaxis	
group	 (Arm	B)	 in	 “Total”	 or	 domain	 scores	 at	 any	 time	 during	 the	
study.
3.1.3 | Haemophilia‐specific Quality of Life in 
adolescents (Haemo‐QoL SF)
The	 impact	of	emicizumab	prophylaxis	on	Haemo‐QoL	SF	 is	only	
presented	 for	 those	 participants	 previously	 treated	 with	 pro‐
phylactic	 BPAs	 (Arm	C)	 because	 too	 few	 adolescents	 completed	
this	 questionnaire	 in	Arms	A	 (n	=	3)	 and	B	 (n	=	2)	 for	meaningful	
analysis.
At	baseline,	mean	(95%	CI)	Haemo‐QoL	SF	“Total”	score	was	30.7	
(24.3,	37.2).	Improvements	from	baseline	with	emicizumab	prophy‐
laxis	were	seen	 in	most	domains	of	the	Haemo‐QoL	SF	and	 in	the	
“Total”	score	(Table	4).	Improvements	were	seen	as	early	as	week	5	
and	maintained	through	week	25.
3.1.4 | Health status
At	baseline,	mean	 (95%	CI)	 EQ‐VAS	 scores	were	70.7	 (63.6,	 77.9),	
76.3	 (69.1,	83.5)	and	75.8	 (68.4,	83.2)	 in	Arms	A,	B	and	C,	respec‐
tively.	Baseline	mean	(95%	CI)	EQ‐5D‐5L	IUS	scores	were	0.72	(0.63,	
0.81),	 0.67	 (0.52,	 0.82)	 and	 0.74	 (0.67,	 0.81)	 in	 Arms	 A,	 B	 and	 C,	
respectively.	 For	 some	 dimensions	 of	 the	 EQ‐5D‐5L	 (eg,	 anxiety),	
a	 considerable	 number	 of	 participants	 reported	 “never”	 having	 a	
TA B L E  2  Haemophilia‐related	quality	of	life	in	adults.	Mean	Haem‐A‐QoL	domain	and	total	scores	at	baseline
Haem‐A‐QoL 
domain
Previously on episodic BPAs Previously on prophylactic BPAs
Arm A: Emicizumab prophylaxis 
n = 29 
Mean scorea (95% CI)
Arm B: No prophylaxis 
n = 16 
Mean scorea (95% CI)
Arm C: Emicizumab prophylaxis 
n = 21 
Mean scorea (95% CI)
Physical	Health 52.4	(44.4,	60.4) 57.2	(46.1,	68.3) 59.5	(48.0,	71.1)
Feelings 36.9	(27.2,	46.5) 32.4	(18.0,	46.8) 47.9	(32.6,	63.2)
View	of	Yourself 45.3	(37.6,	53.1) 48.8	(38.7,	58.8) 52.1	(40.9,	63.4)
Sports	&	Leisureb 58.0	(45.4,	70.6) 66.9	(55.4,	78.4) 67.3	(47.8,	86.8)
Work	&	Schoolb 36.7	(23.4,	49.9) 42.3	(31.2,	53.4) 50.3	(33.4,	67.1)
Dealing	with	
Haemophilia
26.7	(19.2,	34.3) 21.9	(14.0,	29.8) 28.2	(14.7,	41.7)
Treatment 36.3	(26.6,	46.0) 45.7	(34.0,	57.4) 48.5	(37.5,	59.5)
Future 48.4	(38.7,	58.1) 55.3	(41.6,	69.0) 54.5	(44.0,	65.0)
Family	Planningb 27.1	(9.5,	44.7) 44.9	(21.8,	68.0) 43.8	(9.7,	77.8)
Partnership	&	
Sexuality
26.4	(12.6,	40.3) 15.6	(4.4,	26.8) 34.9	(19.2,	50.7)
Total	score 41.1	(34.0,	48.3) 44.6	(36.7,	52.5) 49.4	(40.4,	58.4)
BPA,	bypassing	agents;	CI,	confidence	limit;	Haem‐A‐QoL;	Haemophilia	Quality	of	Life	Questionnaire	for	Adults.
aScales	range	from	0	(no	impairment)	to	100	(high	impairment).	
bParticipants	had	the	option	to	choose	“not	applicable”	for	these	domains.	At	week	1,	the	number	of	respondents	(n)	for	Arms	A,	B	and	C,	respectively,	
was	20,	13	and	12	for	“Sports	&	Leisure,”	14,	11	and	8	for	“Family	Planning”	and	20,	13	and	16	for	“Work	&	School”.	
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problem	at	baseline,	and	this	may	have	limited	the	ability	to	detect	
an	improvement	in	some	items.
Improvements	 in	 EQ‐VAS	 and	 EQ‐5D‐5L	 IUS	with	 emicizumab	
prophylaxis	were	seen	as	early	as	week	5,	maintained	through	week	
25,	and	similar	regardless	of	previous	treatment	regimen	(Figure	4).	In	
the	no	prophylaxis	group	(Arm	B),	EQ‐VAS	and	EQ‐5D‐5L	IUS	scores	
remained	near	baseline	levels	or	decreased	slightly	during	the	study.
Among	 participants	 previously	 treated	with	 episodic	 BPAs,	 the	
difference	in	adjusted	mean	scores	between	the	emicizumab	prophy‐
laxis	group	(Arm	A)	and	the	no	prophylaxis	group	(Arm	B)	at	week	25	
was	statistically	significant	in	favour	of	emicizumab	for	both	the	EQ‐
VAS	(Δ	=	−9.72;	95%	CI:	−17.6,	−1.82;	P	=	0.0171)	and	IUS	(Δ	=	−0.16,	
95%	CI:	−0.25,	−0.07;	P	=	0.0014).	Throughout	 the	 study,	 a	greater	
proportion	 of	 participants	 in	 the	 emicizumab	 prophylaxis	 groups	
F I G U R E  2  Haem‐A‐QoL	(adults)	“Total”	score.	Scale	ranges	from	0	(no	impairment)	to	100	(high	impairment).	BPA,	bypassing	agent;	CI,	
confidence	interval;	Haem‐A‐QoL,	Haemophilia	Quality	of	Life	Questionnaire	for	Adults;	QW,	once	a	week.	A.	Mean	score	over	time.	B.	
Cumulative	distribution	plot	of	transformed	“Total”	change	scores	from	baseline	to	week	25
Mean 'Total' score over time (A)
Cumulative distribution plot of transformed ‘Total’ change scores from baseline to week 25(B)
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(Arms	A	and	C)	 than	 in	 the	no	prophylaxis	group	 (Arm	B)	 achieved	
an	improvement	exceeding	responder	thresholds	(Figure	S1C,D).39,40
Mean	EQ‐VAS	and	EQ‐5D‐5L	 IUS	 scores	were	generally	 lower	
(worse)	on	days	when	bleeding	occurred	than	on	regularly	scheduled	
reporting	days	(Figure	S2).
3.1.5 | Work/school absences and hospitalizations
The	 number	 of	 participants	 working	 before	 and	 during	 the	 study	
was	11	in	the	emicizumab	prophylaxis	group	(Arm	A)	and	7	in	the	no	
prophylaxis	group	 (Arm	B).	 In	 the	4	weeks	before	study	entry,	 the	
F I G U R E  3  Haem‐A‐QoL	(adults)	Physical	Health	Domain	score.	Scale	ranges	from	0	(no	impairment)	to	100	(high	impairment).	BPA,	
bypassing	agent;	CI,	confidence	interval;	Haem‐A‐QoL,	Haemophilia	Quality	of	Life	Questionnaire	for	Adults;	QW,	once	a	week.	A,	Mean	
score	over	time.	B,	Cumulative	distribution	plot	of	transformed	“Physical	Health”	domain	change	scores	from	baseline	to	week	25
Mean 'Physical Health' score over time 
Cumulative distribution plot of transformed ‘Physical Health’ domain change scores from baseline to week 25 (B)
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mean	proportion	of	missed	work	days	 (95%	CI)	was	5%	 (0%,	12%)	
in	Arm	A	 and	 13%	 (2%,	 25%)	 in	Arm	B.	 This	 remained	 essentially	
unchanged	 in	both	groups	 (7%	 [0%,	15%]	 and	14%	 [8%,	19%],	 re‐
spectively)	during	the	study.	For	participants	previously	treated	with	
prophylactic	 BPAs	 (Arm	 C),	 the	 mean	 proportion	 of	 missed	 work	
days	(95%	CI)	decreased	from	9%	(0%,	23%)	in	4	weeks	before	study	
entry	to	3%	(0%,	8%)	during	emicizumab	prophylaxis.
Only	four	participants	in	Arms	A	and	B	(previously	treated	with	
episodic	BPAs)	were	attending	school	during	the	study.	Seventeen	
participants	previously	treated	with	prophylactic	BPAs	(Arm	C)	were	
attending	 school,	 and	 the	mean	proportion	of	missed	 school	 days	
(95%	CI)	was	28%	(6%,	50%)	during	4	weeks	before	study	entry	and	
5%	(0%,	11%)	during	emicizumab	prophylaxis.
The	mean	(95%	CI)	number	of	days	hospitalized	was	1.9	(0.0,	5.1)	
with	emicizumab	prophylaxis	(Arm	A),	4.2	(0.0,	8.9)	with	no	prophy‐
laxis	(Arm	B)	and	0.7	(0.0,	1.5)	with	emicizumab	prophylaxis	in	partic‐
ipants	previously	treated	with	prophylactic	BPAs	(Arm	C).
4  | DISCUSSION
The	 results	 of	 this	 analysis	 demonstrate	 that	 participants	 receiv‐
ing	once	weekly	emicizumab	prophylaxis	 in	HAVEN	1	experienced	
statistically	 significant	 and	 clinically	 meaningful	 improvements	 in	
haemophilia‐specific	 QoL	 and	 overall	 health	 status.	 On	 all	 meas‐
ures,	 improvements	were	 seen	as	 early	 as	week	5	 and	maintained	
through	 week	 25.	 Moreover,	 improvements	 from	 baseline	 were	
similar	regardless	of	whether	previous	BPA	use	was	episodic	or	pro‐
phylactic.	These	improvements	with	emicizumab	were	likely	due	to	
a	combination	of	substantial	reductions	in	bleeding,	the	low	rate	of	
mostly	mild	adverse	events	and	the	once	weekly	subcutaneous	dos‐
ing	regimen.29
TA B L E  3  Effect	of	emicizumab	prophylaxis	on	haemophilia‐related	quality	of	life	in	adults.	Mean	change	from	baseline	to	week	25	in	
Haem‐A‐QoL	domain	and	total	scoresa
Domain
Previously on episodic BPAs Previously on prophylactic BPAs
Arm A: Emicizumab prophylaxis n = 25b 
Mean Δ (95% CI)
Arm B: No prophylaxis n = 14b 
Mean Δ (95% CI)
Arm C: Emicizumab prophylaxis n = 8b 
Mean Δ (95% CI)
Physical	Healthc −19.8	(−28.8,	−10.8) 0.4	(−9.2,	9.9) −15.0	(−36.2,	6.2)
Feelings −14.8	(−25.9,	−3.6) 6.7	(−1.2,	14.6) −14.1	(−35.1,	7.0)
View	of	Yourself −12.2	(−19.9,	−4.6) 2.5	(−6.0,	11.0) −6.3	(−21.0,	−8.5)
Sports	&	leisurec,d −9.8	(−21.6,	2.0) 2.1	(−5.7,	9.8) −40.8	(−115.6,	33.9)
Work	&	Schoold −13.1	(−20.8,	−5.3) 8.3	(−9.8,	26.5) −21.9	(−46.3,	2.6)
Dealing	with	Haemophilia −4.0	(−11.7,	3.7) 8.3	(−2.0,	18.7) −20.8	(−35.7,	−5.9)
Treatment −9.3	(−16.5,	−2.0) 2.2	(−4.6,	9.1) −24.6	(−50.1,	0.9)
Future −13.8	(−23.6,	−4.0) −2.5	(−15.3,	10.3) −17.5	(−36.1,	1.1)
Family	Planningd 10.9	(−4.6,	26.3) −3.1	(−16.5,	10.3) −43.8	(NE)e
Partnerships	&	Sexuality −2.3	(−12.6,	8.0) 3.6	(−5.4,	12.6) −6.3	(−17.3,	4.8)
Total	scorec −10.7	(−16.5,	−4.8) 2.5	(−2.5,	7.4) −16.4	(−33.4,	0.6)
BPA,	bypassing	agent;	CI,	confidence	interval;	Haem‐A‐QoL,	Haemophilia‐Specific	Quality	of	Life	Questionnaire	for	Adults;	NE,	not	evaluable.
aScales	range	from	0	(no	impairment)	to	100	(high	impairment);	negative	values	indicate	an	improvement	from	baseline.	
bOnly	includes	those	participants	with	results	at	both	baseline	and	week	25.	
cResponder	thresholds	defined	for	“Physical	Health”	(−10),	“Sports	and	Leisure”	(−10)	and	“Total”	score	(−7).38 
dParticipants	could	choose	“not	applicable”	for	these	domains.	The	number	of	participants	with	results	at	both	baseline	and	week	25	in	Arms	A,	B	and	
C,	respectively,	was	15,	11	and	3	for	“Sports	&	Leisure,”	9,	8	and	1	for	“Family	Planning”	and	15,	9	and	6	for	“Work	&	School”.	
eOnly	1	participant	had	results	at	both	baseline	and	week	25.	
TA B L E  4  Effect	of	emicizumab	prophylaxis	on	haemophilia‐
related	quality	of	life	in	adolescents.	Mean	change	from	baseline	to	
week	25	in	Haemo‐QoL	SF	domain	and	“Total”	scoresa
Domain
Previously on 
prophylactic BPAs
Arm C: Emicizumab 
prophylaxis 
n = 13b 
Mean Δ (95% CI)
Physical	Health −24.5	(−32.8,	−16.3)
Feelings −3.9	(−13.4,	5.7)
View	of	Yourself −12.0	(−25.1,	1.1)
Family −15.9	(−31.0,	−0.7)
Friends 12.2	(−3.8,	28.2)
Other	People −12.5	(−20.2,	−4.8)
Sports	&	School −21.2	(−34.0,	−8.3)
Dealing	with	Haemophilia −8.2	(−17.2,	0.9)
Treatment −11.1	(−18.5,	−3.6)
Total	score −11.4	(−16.6,	−6.3)
BPA,	 bypassing	 agent;	 CI,	 confidence	 interval;	 Haem‐A‐QoL,	
Haemophilia‐Specific	Quality	of	Life	Assessment	for	Children.
aScales	range	from	0	(no	impairment)	to	100	(high	impairment);	negative	
values	indicate	an	improvement	from	baseline.	
bOnly	calculated	for	those	participants	with	results	at	both	baseline	and	
week	25.	
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During	emicizumab	prophylaxis	in	HAVEN	1,	mean	Haem‐A‐QoL	
and	Haemo‐QoL	SF	“Total”	and	“Physical	Health”	domain	scores	im‐
proved	from	near	the	middle	of	the	scale	to	below	the	lower	third	
of	 the	 scale	 regardless	 of	 previous	 treatment	 regimen,	 suggesting	
a	marked	 improvement	 in	haemophilia‐related	QoL.	 Improvements	
seen	 in	Haem‐A‐QoL	“Work	&	School”	and	“Sports	&	Leisure”	do‐
mains	and	the	Haemo‐QoL	SF	“Sports	&	School”	domain,	as	well	as	
the	 low	rate	of	hospitalizations	and	work	or	school	absences,	sug‐
gest	an	overall	improvement	in	the	ability	to	engage	in	activities	of	
daily	life.	This	is	supported	by	the	high	rate	of	participants	achieving	
responder	thresholds	on	Haem‐A‐QoL	“Total”	and	“Physical	Health”	
domain	scores.	Currently,	there	is	no	consensus	on	how	changes	in	
HRQoL	outcomes	should	be	interpreted,	but	the	responder	thresh‐
olds	used	in	this	study	provide	an	estimate	of	notable	improvements	
that,	when	 combined	with	 other	 findings,	 suggest	meaningful	 im‐
provements	in	participants’	lives.38	Further	longitudinal	assessments	
are	needed,	however,	to	quantify	how	the	HRQoL	changes	observed	
with	emicizumab	prophylaxis	correspond	to	real‐life	improvements.
In	addition	to	improvements	in	HRQoL,	emicizumab	prophylaxis	
resulted	 in	 statistically	 significant	 improvements	 in	 overall	 health	
status	as	measured	by	the	EQ‐VAS	and	EQ‐5D‐5L	IUS.	As	has	been	
seen	 in	 other	 studies,24,42	 EQ‐5D‐5L	 IUS	 scores	 were	 generally	
F I G U R E  4  Health	status	as	measured	
by	the	European	Quality	of	Life	5‐
Dimensions	5‐levels	(EQ‐5D‐5L)	visual	
analogue	scale	(EQ‐VAS)	and	index	utility	
score	(IUS).	On	the	EQ‐VAS,	scores	ranged	
from	0	(worst	imaginable)	to	100	(best	
imaginable).	On	the	IUS,	scores	ranged	
from	−0.594	(extreme	problems	on	all	
dimensions)	to	1	(no	problems	on	all	
dimensions).	BPA,	bypassing	agent;	CI,	
confidence	interval.	A,	Mean	EQ‐VAS	over	
time.	B,	Mean	EQ‐5D‐5L	IUS	over	time
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worse	 on	 the	 days	 on	which	 bleeding	 occurred	 than	 on	 regularly	
scheduled	reporting	days.
The	strengths	of	this	study	include	the	use	of	psychometrically	
validated,	haemophilia‐specific	and	age‐appropriate	HRQoL	instru‐
ments.33,43	The	inclusion	of	overall	health	status	measures	that	are	
not	 disease‐specific	 provides	 a	 valuable	 complement	 to	 the	 dis‐
ease‐specific	outcomes.	The	 separate	 analyses	 for	participants	on	
different	previous	treatment	regimens	are	also	a	strength,	providing	
insights	on	how	switching	to	emicizumab	prophylaxis	affected	out‐
comes	for	participants	with	different	treatment	histories.	This	study	
was	 limited	by	 the	 small	 number	of	 adolescents	 in	Arms	A	and	B,	
making	it	difficult	to	evaluate	the	impact	of	emicizumab	prophylaxis	
versus	no	prophylaxis	on	HRQoL	and	school	attendance	in	this	age	
group.
5  | CONCLUSIONS
This	 analysis	 of	 HAVEN	 1	 demonstrates	 that	 the	 substantial	 re‐
ductions	 in	 bleeding	 seen	 with	 emicizumab	 prophylaxis29 were 
accompanied	by	substantial	 and	meaningful	 improvements	 in	 the	
daily	lives	of	PwHA	with	inhibitors.	Improvements	in	haemophilia‐
specific	QoL	 and	 overall	 health	 status	were	 apparent	 as	 early	 as	
the	 first	 assessment	 after	 the	 start	 of	 treatment	 and	maintained	
throughout	 the	 study.	 Importantly,	 improvements	 among	 par‐
ticipants	 previously	 treated	with	 prophylactic	BPAs	mirrored	 the	
improvements	 seen	 in	 participants	 previously	 on	 episodic	 BPAs.	
These	findings	suggest	that	emicizumab	prophylaxis	can	help	meet	
the	needs	of	PwHA	with	inhibitors	for	effective,	less	burdensome	
prophylaxis.
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